Perforin and resistance to SARS coronavirus 2 - 22/07/20
Doi : 10.1016/j.jaci.2020.05.007
Louise Cunningham, MB a, ⁎ 
, Peter Simmonds, PhD b, Ian Kimber, PhD c, David Arthur Basketter, FRCPath d, John Paul McFadden, DM a
, Peter Simmonds, PhD b, Ian Kimber, PhD c, David Arthur Basketter, FRCPath d, John Paul McFadden, DM a a St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital, London, United Kingdom
b Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
c Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
d DABMEB Consultancy Ltd, Sharnbrook, Bedfordshire, United Kingdom
∗Corresponding author: Louise Cunningham, MB, C/O St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital, London, UK.C/O St John’s Institute of DermatologyGuy’s and St Thomas’ HospitalLondonUK
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Key words : Perforin, COVID, SARS, coronavirus, SARS-CoV-2, hemophagocytic lymphohistiocytosis, macrophage activation syndrome, cytokine storm, cytokine release, perforinopathies, natural killer, cytotoxic T lymphocyte, BCG, metformin
Il testo completo di questo articolo è disponibile in PDF.
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 1
P. 52-53 - Luglio 2020 Ritorno al numero
Articolo precedente
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Update on JACI’s evolution
- Zuhair K. Ballas
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.